Eltrombopag Is Well-Tolerated in Pediatric Severe Aplastic Anemia
Researchers sought to determine whether eltrombopag would improve responses in children with refractory/relapsed or previously untreated severe aplastic anemia.
Researchers sought to determine whether eltrombopag would improve responses in children with refractory/relapsed or previously untreated severe aplastic anemia.
Researchers sought to determine risk factors for developing secondary myeloid neoplasm in patients with severe aplastic anemia.
Researchers sought to determine whether a novel approach to haploidentical bone marrow transplantation would be effective in patients with aplastic anemia.
Researchers sought to determine outcomes of transplantation in relapsed/refractory severe anemia with the use of a haploidentical donor.
Researchers sought to determine whether patients with aplastic anemia and PNH would benefit from a second SARS-CoV-2 vaccination.
Researchers sought to determine whether adding eltrombopag to standard immunosuppression therapy would be effective for patients with severe aplastic anemia.
Researchers sought to determine whether adding eltrombopag to standard immunosuppressive therapy would improve outcomes in children with SAA.
Researchers sought to determine whether treatment with eltrombopag and immunosuppression would reduce risk of relapse for patients with severe aplastic anemia.
Researchers sought to find possible relationships between mutations in human leukocyte antigen alleles and clinical features associated with aplastic anemia.
Improvement seen in the rate, rapidity, strength of hematologic response in previously untreated patients with severe aplastic anemia